Status:
WITHDRAWN
Use of Tranexamic Acid in Facial Fillers
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Injection Site Bruising
Eligibility:
All Genders
18-89 years
Phase:
PHASE4
Brief Summary
The overall purpose of this study is to evaluate the safety and efficacy of co-administration of tranexamic acid (TXA) with hyaluronic acid (HA) in reducing swelling, bruising and pain after facial in...
Eligibility Criteria
Inclusion
- Age equal to or greater than 18 but less than or equal to 89 years.
- Medically appropriate to undergo elective facial filler injection at UW Health by principal investigator
- English speaking
Exclusion
- Minors or under the age of 18
- Patient over the age of 89
- Pregnant or breast-feeding women
- Individuals unable to give consent due to another condition such as impaired decision-making capacity.
- Participants with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis
- Concurrent use of estrogen
- Participant undergoing unilateral facial filler injections
- Participants with history of hypersensitivity to TXA or any of the other ingredients
- Participants that are on current therapeutic anticoagulation therapy
- Participants with stage 2 or greater renal failure
- Participants on hemo- or peritoneal dialysis
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04373603
Start Date
July 1 2022
End Date
July 1 2023
Last Update
July 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States, 53792